← All Acrivon Therapeutics, INC filings

Acrivon Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ACRV
Acrivon Therapeutics, INC
10-K: Acrivon Therapeutics 2025 Annual Report Highlights Clinical Progress, Financials
Acrivon Therapeutics' 2025 annual report details significant clinical advancements for its oncology pipeline, including positive interim data for ACR-368 in endometrial cancer and progress for ACR-2316, alongside continued operating losses and a need for future funding.
NASDAQ
ACRV
Acrivon Therapeutics, INC
10-K: Acrivon Therapeutics Reports Promising Endometrial Cancer Data, Prioritizes Lead Program
Acrivon Therapeutics' 10-K filing highlights the company's focus on precision oncology, positive clinical data for ACR-368 in endometrial cancer, and advancements in its AP3 platform.
NASDAQ
ACRV
Acrivon Therapeutics, INC
10-K: Acrivon Therapeutics Outlines Share Structure and Corporate Governance in SEC Filing
Acrivon Therapeutics details its common and preferred stock structure, voting rights, and anti-takeover provisions in a recent SEC filing.